The prior year say-on-pay vote received approximately 95% support, well above the 70% threshold that would require visible changes. The pay structure is strongly performance-oriented: 94% of the CEO's target compensation is variable and at-risk, with annual bonuses tied to pre-established clinical, regulatory, and business development goals that paid out at 160% of target based on genuine achievements (NDA filings, new drug approvals, pipeline nominations). PTGX's 3-year stock return of +326% dramatically outperforms the XBI — SPDR S&P Biotech ETF by +265 percentage points, meaning the above-target incentive payouts are well-aligned with outstanding shareholder returns; the company also has a meaningful clawback policy in place.

Non-audit fees (tax fees of $29,565 plus other fees of $7,200, totaling $36,765) represent only about 2% of audit fees of $1,796,700, well below the 50% threshold that would raise independence concerns. Auditor tenure is not disclosed in the proxy, so the tenure trigger cannot fire per policy. EY is a Big 4 firm fully appropriate for a $6.5 billion market cap company, and no material financial restatements were identified.